Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.30 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | GRM8 | O00222 | 1/20 | 0.30 |
| ▸ | GRM6 | O15303 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433841 | 0.81 | SMN1; SMN2 (0.30) | APLNRSMN1; SMN2POLB | |
| SCHEMBL2433838 | 0.81 | SMN1; SMN2 (0.30) | APLNRSMN1; SMN2POLB | |
| SCHEMBL2433836 | 0.81 | SMN1; SMN2 (0.30) | APLNRSMN1; SMN2POLB | |
| SCHEMBL19933348 | 0.81 | HSD11B1 (0.39) | APLNR | |
| SCHEMBL21474584 | 0.81 | HSD11B1 (0.43) | APLNRGRM5TSHR | |
| SCHEMBL21834034 | 0.79 | FFAR3 (0.54) | APLNRLMNASMN1; SMN2BLMPOLB | |
| SCHEMBL21834030 | 0.79 | FFAR3 (0.54) | APLNRLMNASMN1; SMN2BLMPOLB | |
| SCHEMBL28048449 | 0.79 | APLNR (0.40) | APLNREPHX2LMNASMN1; SMN2BLM | |
| SCHEMBL16513188 | 0.78 | KDM4E (0.30) | LMNACYP2C19 | |
| SCHEMBL4443085 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060504-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070042990-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| EP-1399439-A1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | Bayer HealthCare AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1397363-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098880-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098873-A1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-4797502-A | ENZYME INHIBITORS, ANTILIPEMIC AGENTS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1989-01-10 | — | — | US | disclosed |
| US-4675428-A | Sulfonic acid ester derivatives useful as antilipemic agents | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1987-06-23 | — | — | US | disclosed |
| EP-0117876-B1 | SULFONIC ESTER DERIVATIVES AND PROCESS FOR THEIR PREPARATION | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1986-12-10 | — | — | EP | disclosed |
| EP-0117876-A1 | SULFONIC ESTER DERIVATIVES AND PROCESS FOR THEIR PREPARATION | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1984-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042990-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | APLNR 4730/4885EPHX2 1295/4885LMNA 981/4885 |
| US-20070060504-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | APLNR 4730/4885EPHX2 1295/4885LMNA 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.